DCT and melanoma: Among different potential targets specific for B16 melanoma cell line [28], the cancer vaccine was a peptide mix including the melanoma-specific Tyrosinase-related protein 2 (Trp2180–188) and two mutated peptides (e.g. MUT30 and MUT44) [29].